Evaluating the benefits of using secukinumab rather than standard treatments as the first systemic treatment in moderate to severe psoriasis
- Registry ID
- EUCTR2016-003592-21
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE4
- Sponsor
- Novartis Pharmaceuticals UK Limited
- Start date
- 2016-11-15
- Completion date
- 2016-12-07
- Last update
- 2026-08-16
Conditions
- Moderate to severe plaque psoriasis
Summary
The primary objective is to demonstrate, in systemic treatment-naïve patients with moderate to severe plaque psoriasis, that the cumulative effect of treatment with secukinumab 300 mg over 32 weeks, as measured by the area under the curve (AUC) for PASI percent change from baseline, is superior to that seen with a standard treatment pathway.
Locations
View on source registry